Key result
ESC and NICE guidelines for stable angina prefer beta-blockers and calcium channel blockers as first-line treatment, despite all antianginal drugs being equally effective without reducing mortality.
Why the study?
Randomised trials show antianginal drugs are equally effective without reducing mortality or MI risk, yet guidelines differ in their approaches and prefer beta-blockers and calcium channel blockers as first-line therapy.
Comparison
European Society of Cardiology guidelines vs National Institute for Health and Care Excellence guidelines
Design
Critical review of guidelines
Authors
Loading...
Guidelines' first-line preference for beta-blockers and CCBs in stable angina lacks RCT superiority; leaves open whether recommendations warrant re-evaluation.
This critical review highlights the discrepancy between RCT evidence showing equal efficacy among antianginal drugs and current ESC/NICE guideline preferences for beta-blockers and calcium channel blockers as first-line therapy.
Rousan et al. (2019) conducted a review in stable angina. Pharmacological therapy guidelines was evaluated. ESC and NICE guidelines for stable angina prefer beta-blockers and calcium channel blockers as first-line treatment, despite all antianginal drugs being equally effective without reducing mortality.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: